Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272128 | 1.00 | CHRM1 (0.58) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL28926380 | 0.89 | ADRA1A (0.53) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL25409838 | 0.88 | ADRA1A (0.54) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL31366629 | 0.88 | ADRA1A (0.54) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL25409835 | 0.88 | ADRA1A (0.54) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL21272096 | 0.87 | CHRM1 (0.77) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL7722823 | 0.85 | GABRA1 (0.70) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL3142613 | 0.85 | GABRA1 (0.70) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL13585027 | 0.83 | ADRA1A (0.61) | CHRM1ADRA1AGABRA1GABRA5GABRA3 | |
| SCHEMBL11464920 | 0.83 | ADRA1A (0.61) | CHRM1ADRA1AGABRA1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3535253-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ADRA1A 67/4885GABRA1 63/4885 |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ADRA1A 67/4885GABRA1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.